Legal status
Legal status
  • 1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane
CAS Number
PubChem CID
Chemical and physical data
Molar mass228.12 g·mol−1
3D model (JSmol)
  • C1C2C1(CNC2)C3=CC(=C(C=C3)Cl)Cl
  • InChI=1S/C11H11Cl2N/c12-9-2-1-7(3-10(9)13)11-4-8(11)5-14-6-11/h1-3,8,14H,4-6H2 ☒N
 ☒NcheckY (what is this?)  (verify)

DOV 216,303 is an experimental antidepressant drug originally developed by DOV Pharmaceutical and was licensed to Merck & Co. in 2004;[1] Merck and DOV terminated their relationship in December 2006.[2]: 12 [3]

It is a triple reuptake inhibitor (TRI), or serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI).[4] It is the racemic mixture of amitifadine (DOV-21,947) and its (–)-enantiomer, DOV-102,677. Its IC50 values for SERT, NET, and DAT are Ki 14 nM, 20 nM, and 78 nM, respectively.[4]

As of March 2008, DOV had no intention to further develop DOV-216,303 because the patent on the compound had expired.[2]: 6 

In a mouse model, DOV-216,303 has shown the ability to promote recovery after spinal cord contusion.[5]

See also


  1. ^ McCoy M (August 12, 2004). "Merck and DOV Pharmaceutical In Drug Pact". Chemical & Engineering News.
  2. ^ a b "10-K For the fiscal year ended December 31, 2007". Dov Pharmaceutical via SEC Edgar. March 31, 2008. DOV 216,303 was originally in development for depression; however as the patented composition of matter claim has expired, there are no ongoing clinical trials of DOV 216,303 and none are planned.
  3. ^ "DOV 216303". Adis Insight. Springer Nature Switzerland AG. Retrieved 26 February 2017.
  4. ^ a b Skolnick P, Krieter P, Tizzano J, Basile A, Popik P, Czobor P, Lippa A (2006). "Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor". CNS Drug Reviews. 12 (2): 123–34. doi:10.1111/j.1527-3458.2006.00123.x. PMC 6494125. PMID 16958986.
  5. ^ Chu TH, Cummins K, Stys PK (May 2018). "The triple monoamine re-uptake inhibitor DOV 216,303 promotes functional recovery after spinal cord contusion injury in mice". Neuroscience Letters. 675: 1–6. doi:10.1016/j.neulet.2018.03.050. PMID 29578004. S2CID 5007186.